Journal of Antimicrobial Chemotherapy (2000) 45, 95
© 2000 The British Society for Antimicrobial Chemotherapy
Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae
SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA
The aim of this study was to characterize quinolone resistance mechanisms in strains of Streptococcus pneumoniae with increased MICs of ofloxacin. These strains were also tested for their susceptibility to a battery of quinolone antimicrobial agents, including gemifloxacin. Of the S. pneumoniae isolates used, 27 were susceptible to ofloxacin, 18 intermediate and 48 resistant (ofloxacin MIC <4, 4 and >4 mg/L, respectively). In general, the ofloxacin-susceptible strains had no amino acid substitutions in GyrA, GyrB, ParC or ParE. Moderate increases in MIC were associated with substitutions in the quinolone resistance-determining region (QRDR) of ParC, while the highest MICs were found for strains that also had substitutions in the QRDR of GyrA. The most common substitutions were Ser79
Phe in ParC and Ser81Phe in GyrA. Other substitutions were identified within the QRDR of ParC and outside the QRDR of ParC and ParE; these did not appear to affect susceptibility. The effects of antimicrobial efflux pumps were studied by determining MICs of a range of quinolones in the presence and absence of reserpine, an inhibitor of Gram-positive efflux pumps. Our results indicated that high-level resistance, caused entirely by efflux, was seen in a minority of ofloxacin-resistant S. pneumoniae strains. Testing the susceptibility of quinolone-resistant strains to gemifloxacin, ciprofloxacin, norfloxacin, ofloxacin and trovafloxacin revealed that gemifloxacin was least affected by this large variety of resistance mechanisms and was the only quinolone with MICs of 
0.5 mg/L for all strains in this study. These results suggest that gemifloxacin is highly potent against S. pneumoniae and may also be effective against strains resistant to other quinolones.
* Correspondence address. Microbiology Research, SmithKline Beecham Pharmaceuticals, 1250 S. Collegeville Road, Collegeville, PA 19426-0989, USA. Tel: +1-610-917-6273; Fax: +1-610-917-4617; E-mail: Kenneth_Coleman{at}SBPHRD.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Singh, K. R. Ledesma, K.-T. Chang, J.-G. Hou, R. A. Prince, and V. H. Tam Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model J. Antimicrob. Chemother., September 1, 2009; 64(3): 556 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bagg, M P. Sweeney, A. N Davies, M. S Jackson, and S. Brailsford Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer J. Med. Microbiol., October 1, 2005; 54(10): 959 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sadowy, R. Izdebski, A. Skoczynska, M. Gniadkowski, and W. Hryniewicz High Genetic Diversity of Ciprofloxacin-Nonsusceptible Isolates of Streptococcus pneumoniae in Poland Antimicrob. Agents Chemother., May 1, 2005; 49(5): 2126 - 2129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Azoulay-Dupuis, J. P. Bedos, J. Mohler, P. Moine, C. Cherbuliez, G. Peytavin, B. Fantin, and T. Kohler Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1046 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Christiansen, J. M. Bell, J. D. Turnidge, and R. N. Jones Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001 Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2049 - 2055. [Abstract] [Full Text] [PDF]
|
|